IDEXX Laboratories, Inc. $IDXX Stake Boosted by Franklin Street Advisors Inc. NC

Franklin Street Advisors Inc. NC increased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 10.1% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,131 shares of the company’s stock after purchasing an additional 3,222 shares during the period. Franklin Street Advisors Inc. NC’s holdings in IDEXX Laboratories were worth $18,842,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Opal Wealth Advisors LLC bought a new stake in IDEXX Laboratories in the second quarter worth $29,000. MorganRosel Wealth Management LLC bought a new stake in IDEXX Laboratories in the first quarter worth $26,000. Ameritas Advisory Services LLC bought a new stake in IDEXX Laboratories in the second quarter worth $36,000. Migdal Insurance & Financial Holdings Ltd. boosted its holdings in IDEXX Laboratories by 55.6% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company’s stock worth $35,000 after purchasing an additional 30 shares in the last quarter. Finally, WPG Advisers LLC bought a new stake in IDEXX Laboratories during the first quarter valued at about $37,000. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Trading Down 0.4%

Shares of NASDAQ IDXX opened at $631.19 on Friday. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $688.12. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. The company’s fifty day moving average is $634.52 and its 200-day moving average is $534.79. The stock has a market cap of $50.50 billion, a price-to-earnings ratio of 52.56, a P/E/G ratio of 4.10 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, August 4th. The company reported $3.63 EPS for the quarter, topping analysts’ consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same period last year, the business posted $2.44 earnings per share. The firm’s quarterly revenue was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Equities research analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Leerink Partners upped their price target on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, July 17th. JPMorgan Chase & Co. upped their price target on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the company an “overweight” rating in a report on Monday, August 4th. Wall Street Zen cut shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Sunday, September 28th. Stifel Nicolaus set a $640.00 price target on shares of IDEXX Laboratories in a report on Monday, August 4th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of IDEXX Laboratories in a research report on Saturday, September 27th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $656.50.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Sharon E. Underberg sold 5,450 shares of the business’s stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $651.60, for a total value of $3,551,220.00. Following the completion of the sale, the executive vice president owned 6,156 shares of the company’s stock, valued at $4,011,249.60. The trade was a 46.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Michael G. Erickson sold 406 shares of the business’s stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $649.96, for a total transaction of $263,883.76. Following the completion of the sale, the executive vice president directly owned 11,287 shares of the company’s stock, valued at $7,336,098.52. This represents a 3.47% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 54,057 shares of company stock worth $34,293,468 in the last ninety days. Insiders own 0.98% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.